Autologous Stem Cell Transplantation (ASCT) is a standard of care in relapsed diffuse large B-cell lymphoma (DLBCL) and other lymphoproliferative disorders including relapsed Hodgkin’s disease, mantle or T-cell lymphoma. Carmustine, etoposide, ARA-C, melphalan (BEAM) [1], lomustine, etoposide, ARA-C, melphalan (LEAM) and lomustine, ARA-C, cyclophosphamide, etoposide (LACE) are commonly used con...

DNA Alkylation is thought to be the reason for the efficacy of lomustine while carbamylation has been implicated as the cause for the side effects seen with lomustine treatment such as hepatotoxicity. In the alkylation study we show that lomustine and its metabolites form similar levels of the DNA adducts N⁷ hydroxyethylguanine and O⁶ hydroxyethyldeoxyguanosine. In terms of carbamylation, lomus...

An original reaction mechanism and kinetic parameter estimation has been achieved for lomustine, an anti-cancer active pharmaceutical ingredient (API).

Abstract AIMS Almost all patients with glioblastoma relapse after initial treatment. At relapse, chemotherapy using multi-agent PCV (Procarbazine, Lomustine and Vincristine) or single agent is often employed. an oral agent, therefore spares from additional hospital visits for intravenous vincristine removes the need dietary restrictions while taking procarbazine, so would be attractive option, ...

BACKGROUND Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients...

Galunisertib, a Transforming growth factor-βRI (TGF-βRI) kinase inhibitor, blocks TGF-β-mediated tumor growth in glioblastoma. In a three-arm study of galunisertib (300 mg/day) monotherapy (intermittent dosing; each cycle =14 days on/14 days off), lomustine monotherapy, and galunisertib plus lomustine therapy, baseline tumor tissue was evaluated to identify markers associated with tumor stage (...

BACKGROUND The prognosis for children with malignant glioma is poor. This study was designed to determine whether lomustine and temozolomide following radiotherapy and concurrent temozolomide improves event-free survival (EFS) compared with historical controls with anaplastic astrocytoma (AA) or glioblastoma (GBM) and whether survival is influenced by the expression of O6-methylguanine-DNA-meth...

BACKGROUND AND OBJECTIVES Treatment of acute myeloid leukemia (AML) in older patients remains unsatisfactory. The BGMT 95 trial for older patients set out to improve the outcome of these patients by adding a third drug (lomustine) to a 5+7 idarubicin and cytarabine schedule at induction and evaluating intermediate-dose cytarabine as consolidation. DESIGN AND METHODS A multicenter randomized t...

Lomustine (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea; CCNU) is a synthetic orally active nitrosourea marketed in the past few years for the chemotherapy of carcinoma, particularly of the brain. The major toxic effects are bone marrow suppression with leucopenia and thrombocytopenia and gastrointestinal effects with nausea and vomiting. Progressive lung changes resulting from cytotoxic drugs ...

BACKGROUND Nonresectable mast cell tumors (MCT) in dogs remain a therapeutic challenge, and investigation of novel combination therapies is warranted. Intermittent administration of tyrosine kinase inhibitors (TKI) combined with cytotoxic chemotherapy may effectively chemosensitize canine MCT while decreasing cost and adverse effects associated with either agent administered as monotherapy. H...